We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Pathway Leads to Skin and Hair Regeneration After Injury

By LabMedica International staff writers
Posted on 25 Aug 2015
The ability of the skin to regenerate after injury has been linked to stimulation of Toll-Like Receptor 3 (TLR3) by double-stranded RNA (dsRNA) released by the damaged skin.

Replacement of skin and hair follicles after wounding through a process known as wound-induced hair neogenesis (WIHN) is a rare example of adult organ regeneration in mammals. More...
As such, WIHN provides a unique model system for deciphering mechanisms underlying mammalian regeneration.

Investigators at Johns Hopkins University (Baltimore, MD, USA) used mouse models to study skin and hair follicle regeneration. Initially, by comparing normal mice to an inbred strain with restricted ability to regenerate skin, they found that expression of TLR3 was three times higher in the normal animals.

The application of synthetic dsRNA to mouse skin wounds led to a greater number of regenerated follicles. In contrast, treatment with a substance that broke up dsRNA decreased the number of regenerated follicles, and regeneration was nearly abolished in mice deficient in TLR3.

Results published in the August 6, 2015, issue of the journal Cell Stem Cell revealed that the process that began with dsRNA activation of TLR3 continued to hair follicle regeneration through the action of TLR3's downstream effectors IL-6 (interleukin-6) and STAT3 (signal transducer and activator of transcription 3). Loss of TLR3, IL-6Ra, or Stat3 proteins reduced WHIN in mice with damaged skin.

“Our study uncovers a novel role for a protein that works as a master regulator of regeneration in the skin,” said senior author Dr. Luis A. Garza, associate professor of dermatology at Johns Hopkins University. “Medications that turn on this protein have the powerful potential to decrease scarring as healing of wounds takes place, thereby promoting skin and hair follicle regeneration.”

“A lot of human disability is from scarring,” said Dr. Garza. “After a heart attack, we are really good at replacing the blood flow, but it is the scar on the heart afterward that is the real problem. We and others in the field of regenerative medicine are interested in how to enhance or trigger regeneration in such situations.”

Related Links:
Johns Hopkins University



New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.